QUEBEC, Aug. 19 /CNW Telbec/ - Victhom Human Bionics Inc., "Victhom"
(TSX: VHB), is pleased to announce that its Neurobionix business unit has
obtained ISO 13485:2003 certification for its Quality Management System to
manufacture medical devices. This certification, an internationally recognized
management system standard developed by the International Organization for
Standardization (ISO), is a requirement for the manufacturing of a commercial
medical device. Victhom's Neurobionix business unit manufacturing department
produces medical devices such as implantable neuromodulation products.
"Achieving ISO 13485:2003 certification is an important corporate
milestone for Neurobionix," said Mr. Nader Kameli, Chief Operating Officer of
the Neurobionix business unit. "As all commercially available implantable
devices have to be manufactured in compliance with ISO 13485 standards, this
accomplishment is timely progress towards the commercialization of
Neurostep (TM) in 2009," he continued. "Attaining ISO certification is another
demonstration of our commitment to the quality of our products and processes.
ISO certification will give our customers and business partners added
confidence in our ability to develop technologically advanced products at
quality standards generally associated with larger companies," he explained.
"Our success in achieving this certification is due to the tremendous
dedication and teamwork of all employees in the Neurobionix business unit",
said Joelle Pelletier, Director of Quality Assurance. "Neurobionix is focused
on providing the highest quality products and our team continuously strives to
improve on the delivery of this promise," said Mrs. Pelletier. She also added
that ISO registration supports Neurobionix's quality commitment to its patient
and physician customers.
"This new accomplishment comes at the right time for Victhom. In 2009,
the Company plans to begin commercialization of its neuromodulator, the
Neurostep(TM). Obtaining this certification highlights our rigor and
expertise, providing the Company with an additional asset for future marketing
efforts," said Mr. Normand Rivard, Victhom's acting President and Chief
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
For further information:
For further information: Normand Rivard, Acting President & CFO, Victhom
Human Bionics Inc., (418) 872-5665, Fax: (418) 872-6926,
email@example.com; Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234,
firstname.lastname@example.org; Source: Victhom Human Bionics Inc. (www.victhom.com)